Nexentis Announces Reverse Stock Split

Ness Ziona, Israel, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Nexentis Technologies Inc. (NASDAQ: NXTS) (“Nexentis” or the “Company”), a drug discovery company that also invests in solar energy assets based on the RTB (Ready to Build) business model, announced that its Board of Directors has approved a one-for-five (1-for-5) reverse stock split of its common stock that is scheduled to become effective for Nasdaq purposes on November 9, 2026. Beginning on November 9, 2026, the Company’s common stock will trade on the Nasdaq Capital Market on a split adjusted basis under a new CUSIP number 80512Q709. The Company’s common stock will continue to trade on the Nasdaq Capital Market under the symbol “NXTS.” As previously disclosed, at the Special Meeting of the Stockholders of Nexentis held on April 30, 2026, the Company’s stockholders approved a proposal authorizing the Company’s Board of Directors, among other things, to effect one or more reverse stock splits at a ratio of not less than 1-for-2 and not more than 1-for-500 in order to increase the per share price and bid price of the Company’s common stock to regain compliance with the continued listing requirements of Nasdaq and make the common stock more attractive to certain institutional investors, which would provide for a stronger investor base.